ABN 16 165 160 841

ASX RELEASE **1 August 2025**

Change of Registered Office and Principal Place of Business

Amplia Therapeutics Limited ("ATX" or "the Company") advises that it has today changed its Registered Office and Principal Place of Business to:

Level 5, 90 William Street
Melbourne VIC 3000.

- End -

This ASX announcement was approved and authorised for release by the Company Secretary.

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn.